REGEMAT 3D and Xpect INX join forces to provide full solutions in bioprinting
With the ever growing demands of the healthcare industry, additive manufacturing aka 3D printing provides compelling solutions to battle the unmet needs of the field. However, those have been restricted to the construction of medical apparatuses such as implants, as well as models such as those used in facial reconstruction.
The idea of using 3D printing to make human tissues is not a new one, but the development of novel biomaterials and new formulas is constantly evolving, in order to achieve reproducible results that mimic in vivo conditions more accurately. The two leading companies in the bioprinting industry REGEMAT3D and Xpect-INX, have joined forces to provide advanced types of bioinks, which when used with versatile systems, can create workable substitutes for human tissues like corneas, breast reconstructions after mastectomy, or to create replacement constructs for damaged hearts.
In the longer term, those techniques could even be capable to go into the clinical setting by creating human organs for immediate transplant.
In these senses, 3D bioprinted cells must be able to grow and function like normal human cells, and interact with existing cells until the body can fully integrate them. The key to this is the use of appropriate and biocompatible materials with the proper bioprinting equipment, which can adapt and be optimized to the needs and parameters of those bioinks. That way, the bioinks provide mechanical strength, a healthy growth environment for the cells and, more importantly, an appropriate architechture via the bioprinting process.
As the world searches for a vaccine to use against Covid-19, with all the delays entailed by testing in labs and in clinical trials, bioinks and 3D bioprinting offer a solution for the future. “For clinical studies, this technology could provide opportunities to culture cells or mini-organs as a model for testing new drugs. In this way we could substantially reduce the number of animal experiments.”
The new partnership agreement between REGEMAT3D and Xpect-INX means a step closer into applying the powers of 3D bioprinting in regenerative medicine applications.
- PreviousTechnological advances to control printing temperatures: Heating and cooling systems for extrusion syringes.
- NextFROM AN EMERGING TECHNOLOGY TO A RESEARCH AND MEDICAL REVOLUTION